Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Dermatologic 1

Conditions

Stomach Neoplasms 5Pancreatic Neoplasms 4Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Melanoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Rectal Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Locally Advanced Pancreatic Cancer 1Liver Neoplasms 1Gestational Trophoblastic Disease 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Neoplasms 1Biliary Carcinoma 1

Interventions

pembrolizumab 23Gemcitabine 9Nivolumab 7Carboplatin 7Trastuzumab 6Early Intervention, Educational 6avelumab 5atezolizumab 5Docetaxel 5Cisplatin 5cemiplimab 4Standard of Care 4Psychiatric Rehabilitation 4Paclitaxel 4Methods 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Fluorouracil 4Fluorodeoxyglucose F18 4Cyclophosphamide 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3pertuzumab 3fludarabine 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × zimberelimab × Gastrointestinal × Clear all
NCT05891171 2026-06-05

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡